Partners & Licensees


Phoenix PharmaLabs is fortunate to have developed alliances with commited, visionary development partners at various leading universities, government agencies and research centers as well as scientific advisors including some of the world's leading experts on opioid analgesics and addictive disease.

 

Strategic Objective

 

The overall strategic objective of Phoenix PharmaLabs (PPL) is to advance our compounds for treatment of moderate to severe acute and chronic pain, opioid addiction therapy and animal health. The market potential for PPL's compounds is much too great for a company the size of ours to adequately address.  Therefore, we will seek licenses with appropriate market leaders that have the resources and motivation to further develop, commercialize and maximize the market potential of PPL’s drugs. We intend to advance our compounds through Proof of Concept (POC) in humans at which point they will be well positioned for out-licensing. It is possible, however, that we could decide to enter one or more license agreements or an acquisition or an IPO before that point is reached. In the meantime we are exploring various potential funding opportunities and strategic collaborations.


 

Phoenix PharmaLabs welcomes inquiries by organizations seeking a beneficial relationship.  Please contact us to explore potential opportunities.

News Flash

Phoenix PharmaLabs Releases New Data Confirming That Their Novel Opioid Shows No Signs of Addiction Potential

 

Phoenix PharmaLabs Releases New Data Confirming That Their <...
More details...


Novel Pinkiller with Little or No Signs of Addiction and Other Serious Opioid Side Effects Patented by Phoenix PharmaLabs

 

Novel Painkiller with Little or No Signs of Addiction and Other Serious Opioi...
More details...


Patent Awarded
"Use of PPL opiate in the treatment of opiate addiction." ...
More details...